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In this study, 206 previously untreated patients with sputum culture positive pulmonary tuberculosis 
were randomized to receive an injection of killed Mycobacterium vaccae as immunotherapy, or of saline 
as placebo, after 1 month of a 6-month chemotherapeutic regime. Not surprisingly in a disease for which 
there is good chemotherapy, the difference in numbers which were culture negative at the end of 
treatment was small, and the final outcome at the latest post-treatment follow-up did not reach statistical 
significance between the two arms of the study. Nonetheless, those receiving immunotherapy showed 
better progression in every parameter measured, suggesting faster and more complete cure. Whereas 
seven of 97 patients receiving immunotherapy required a course of re-treatment and five still had active 
disease after a mean follow-up of 2 yr, 13 of 109 placebo recipients required re-treatment and nine still 
had active disease at the end of the study. Only one patient receiving M. vaccae plus chemotherapy died 
of tuberculosis, compared with four of those receiving chemotherapy alone. 
A degree of drug resistance was shown by the bacilli cultured from 25 of 175 (14%) patients, and seven 
of them (4.0%) were multi-drug resistant. Fourteen patients received immunotherapy of whom 13 were 
cured, including all three of those showing multi-drug resistance. Of the 11 patients with drug resistance 
in the control group, eight were cured, and one patient with multi-drug-resistant disease died of 
tuberculosis during re-treatment. 
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Introduction 
A number of claims have been made on theoreti- 
cal grounds, and on the basis of results achieved 
in several countries, that the addition of an injec- 
tion of killed Mycobacterium vaccae as an im- 
munotherapeutic agent improves the treatment 
of tuberculosis (l-3). Other than a recent publi- 
cation of the results of a study carried out under 
very adverse conditions in Nigeria (4) and refer- 
ence to results from The Gambia and Vietnam in 
reviews (5,6), no detailed results of treatment 
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including immunotherapy have been reported 
for newly-diagnosed cases of tuberculosis. 
In the present study, new patients, sputum 
culture positive for Mycobacterium tuberculosis, 
received their first course of treatment for pul- 
monary disease. They were randomized to receive 
a single injection of M. vaccae as immunotherapy, 
or of saline as placebo, 1 month after starting 
chemotherapy. The purpose of the study was to 
assess the influence of immunotherapy on some 
parameters of improvement, including regain of 
body weight, return to normal of the erythrocyte 
sedimentation rate (ESR), resolution of cavities 
and other radiological signs, and disappearance 
of bacilli from the sputum. Patients received the 
standard chemotherapeutic regimen used in 
Romania, most were hospitalized for the initial 
0 1997 W. B. SAUNDERS COMPANY LTD 
14 E. CORLAN ET AL 
TABLE 1. Characteristics of the patients at the time of entering the study 
Mycobacterium vaccae Placebo 
recipients recipients 
Numbers 
Sex 
Mean age (years) 
Bacteriology 
AFB visible in sputum 
Cultures showing resistance 
to one or more drugs 
Multi-drug resistance? 
Clinical 
Mean weight (kg) 
Mean ESR 
Radiology 
No. with cavities 
Cavity surface area 
Mean lesional score 
97 109 
48F 49M 57F 52M 
36.0 f 13.1 36.2 f 13.9 
88197 (91%) 101/109 (93%) 
14/83* (17%) 1 l/92* (12%) 
3/83 (4%) 4/92* (4%) 
56.5 f 9.9 56.1 f 9-3 
60.1 f: 30.0 62.4 zt 3 1.4 
79197 (8 1%) 84/109 (77%) 
54.6 f 66.5 43.1 f 38.6 
2.1 f 0.7 2.1 f 0.6 
AFB, acid-fast bacilli; ESR, erythrocyte sedimentation rate. *Drug-susceptibility patterns 
are not available for 14 M. vaccae recipients and 17 placebo recipients; j-cultures resistant 
to rifampicin and isoniazid, with or without other drugs, 
2 months, and they were followed for up to 3 yr 
after starting treatment. It was hoped that the 
study would lead to a better understanding of 
how immunotherapy works, and to the identifi- 
cation of parameters suitable for evaluation of 
formal trials of the new treatment. 
Materials and Methods 
THE PATIENTS 
The study population c.onsisted of 206 patients 
with sputum cultures positive for tuhercle bacilli 
who. were receiving treatment for the first time 
for pulmonary tuberculosis in Bucharest or 
Brasov. None of them had histories of previous 
treatment for the disease. Sexes were evenly 
distributed, with 105 women and 101 men, and 
their ages ranged from 16 to 80 years. Many of 
the patients presented with advanced disease, 
163 with cavities visible on X-ray. 
Following a computer-generated list of 
random numbers, patients giving informed con- 
sent received an intradermal injection of either 
M. voccue, or saline as placebo. The general 
features of those receiving the different arms of 
intervention are shown in Table 1. 
TREATMENT 
Treatment consisted of 2 months of isoniazid, 
rifampicin, pyrazinamide and streptomycin 
taken twice weekly, followed by 4 months of 
isoniazid and rifampicin taken twice weekly 
(2HRZSJ4HRJ. Doses used were 15 mg kg - ’ 
of isoniazid and rifampicin, 60 mg kg - ’ of 
pyrazinamide and 1 g of streptomycin. Treat- 
ment was not strictly supervised, but free drugs 
were available and prescribed, and it is likely 
that the majority of patients complied with their 
treatment. Patients still sputum culture positive 
at 6 months or 1 yr were prescribed a repeat 
course of treatment. 
At the time of the present study, second-line 
drugs were not generally available in Romania. 
Thus, patients with bacilli showing resistance to 
some of the drugs continued to receive the 
standard chemotherapy. 
The immunotherapy consisted of an intra- 
dermal injection over a deltoid muscle of 
0.1 ml A4. vaccae strain NCTC 11659, Batch 
A5. Each dose contained 1 mg wet weight of 
whole, killed (autoclaved) bacilli in borate- 
buffered saline (1). This injection was given 1 
month after the first course of chemotherapy 
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TABLE 2. Results obtained 2 months after starting chemotherapy, and 1 month after 
intervention 
Mycobacterium vaccae 
recipients 
Placebo 
recipients 
Bacteriology 
Microscopy positive 
Culture positive 
Culture +ve DR 
Clinical 
Body weight 
ESR 
11/88 (13%) 
14/97 (14%) 
4/14 (29%) 
59.6 f 9.2* 
27.4 f 21.4 
(P=O.O8$) 
(P=O.l l$) 
21/100 (21%) 
26/107 (24%) 
7/l 1 (64%) 
58-7 i: 9.6f 
31.3 f 23.7 
DR, drug resistance; ESR, erythrocyte sedimentation rate. *Weight increase PcO.03 
(Student’s t-test); TWeight increase PcO.05 (Student’s t-test); ZTwo-tailed Fisher’s exact test. 
was started. The control group received an 
injection of saline. Patients did not know which 
injection they received, but this was known to 
the physicians. 
CLINICAL EXAMINATION 
Patients were weighed and thoroughly examined 
at diagnosis, intermittently whilst in hospital and 
at outpatient attendances. 
teria, initially, after 2 months of treatment, at the 
end of treatment, 6 months later and at subse- 
quent follow-up attendances. Drug-susceptibility 
studies were performed on initial isolates from 
189 of 225 cases. Venous blood was taken for 
ESR by the Westergren method, at diagnosis 
and after 2, 6 and 12 months. 
STATISTICS 
RADIOLOGICAL INVESTIGATION 
The two-tailed Fisher’s exact test and Student’s 
t-test were used to evaluate most of the results. 
Chest X-rays were performed at diagnosis on all 
patients, and at the end of chemotherapy and 6 
months later in those followed-up. They were 
evaluated by experienced hospital staff who did 
not know which intervention each patient had 
received. A lesional scoring system from 0 to 3 was 
applied to the X-rays. This was based on the origi- 
nal ,method of Simon (7) and of the American 
Thoracic Society modified locally. A score of 0 
reflects normal appearance of lung fields, 1 means 
visible changes occupying no more than 5 cm2 of 
the lung fields, 2 means larger changes up to com- 
plete involvement of a lung, and 3 means changes 
involving one lung or more. In those showing 
cavities, the total area of exposed cavity wall 
was calculated by measuring diameters of visible 
cavities, and multiplying their squares by Pi. 
Results 
All 206 patients had tubercle bacilli cultured 
from their sputum, and 189 had acid-fast bacilli 
(AFB) visible on microscopy. 
As shown in Table 1, the groups for inter- 
vention were well matched other than a slight 
preponderance of more and larger cavities in the 
M. vaccae recipient group. The largest area of 
cavity wall in a patient in the placebo group was 
176 cm’, whereas in the immunotherapy group, 
there was one of this size and, by chance, five 
larger (178,201,221,227 and 443 cm2). Amongst 
the 175 bacillary isolates tested for susceptibility 
to anti-tuberculosis drugs, 25 patients showed 
resistance to at least one drug, and seven patients 
were resistant to rifampicin and isoniazid at least. 
LABORATORY INVESTIGATIONS RESULTS AT 2 MONTHS 
Three sputum samples were taken for examin- The results obtained after 2 months of treatment 
ation by microscopy and culture for mycobac- are shown in Table 2. Although differences did 
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TABLE 3. Results obtained at the end of chemotherapy, 5 months after intervention 
Mycobacterium vaccae Placebo 
recipients recipients 
Total patients 97 109 
Lost to follow-up 3 4* 
Assessed 94 105 
Treatment success 89/91t (98%) 96/105 (91%) 
Bacteriology 
Microscopy positive 4/85t (5%) 8/96t (8%) 
Culture positive 2/91t (2%) (P=O.O6Q 9/105 (9%) 
Culture + ve DR o/14 2/11 (29%) 
Clinical 
Body weight 60.9k 9.5 (4.4 kg)1 59+4& 9.5 (3.3 kg)$ 
ESR 16.7 f 12.1 P=o402** 24.9 f 19.5 
Radiology 
No. still with cavities 47173 (64%) 50177 (65%) 
Cavity surface area 26*2& 34.05 31.9 f 33.411 
Mean lesional score 1.4 f 0.6 1.6 f 0.6 
DR, drug-resistance; ESR, erythrocyte sedimentation rate. *One sputum smear positive 
when lost; j-Data not available on missing numbers; SIncrease in body weight; §Initial 
mean area 74.3 f 77.6 cm2; reduction of 65%; IjInitial mean area 57.2 f 40.6 cm2; reduc- 
tion of 44%; Two-tailed Fisher’s exact test; **Student’s t-test. 
not reach statistical significance 1 month after 
intervention, fewer patients remained culture 
positive in the M. vaccae recipient group, this 
being most noticeable amongst those few 
showing drug resistance. 
RESULTS AFTER 6 MONTHS 
By the end of chemotherapy (see Table 3), only 
two of 91 patients tested in the immunotherapy 
group remained culture positive and were given 
re-treatment, in comparison with nine of 105 in 
the control group requiring re-treatment 
(P=O*O6). There was a significantly greater fall in 
ESR among A4. vaccae recipients (P=O.O02), and 
a trend towards better recovery of body weight. 
There was no difference between the groups in 
surface area of cavity walls seen on X-ray at the 
end of chemotherapy, but the mean reduction 
from the overall initial situation was significantly 
greater in the immunotherapy group (38.3 f 
46.1) compared with 22.6 f 22.3; P<O*Ol), indi- 
cating faster closure of cavities. As shown in the 
footnotes to Table 3, those still with cavities in 
the immunotherapy group show a 65% reduction 
in area of cavity wall since entry to the study, 
compared with 44% in the control group 
(P<O*OOl). 
RESULTS AFTER 1 YR 
One year after diagnosis, and 6 months after the 
end of chemotherapy, bacteriological differences 
between the groups were not significant (Table 4). 
There were three early relapses to culture positivity 
amongst M. vaccae recipients and two in the pla- 
cebo group. Nonetheless, those receiving immuno- 
therapy were, on average, 3 kg heavier (P<O*O7) 
and continued to have a significantly lower ESR 
(P<O+OOOl) than did those in the control group. 
Although, as at the end of chemotherapy, there 
appears to be no difference in resolution of cavities 
between the two groups, better progression to- 
wards resolution is seen after immunotherapy, as 
shown in the footnotes to Table 4. 
RESULTS AT LATEST FOLLOW-UP 
At the most recent follow-up, on average 2 yr 
after the end of chemotherapy, follow-up was 
complete on 80% of patients. In the immuno- 
therapy group, seven patients had required 
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TABLE 4. Results obtained 6 months after the end of chemotherapy 
Mycobacterium vaccae Placebo 
recipients recipients 
Total patients 
Lost to follow-up 
Deaths 
Received re-treatment 
Re-treatment success 
Assessed first course 
First treatment success 
Bacteriology 
Microscopy positive 
Culture positive 
Culture +ve DR 
Clinical 
Body weight 
ESR 
Radiology 
No. still with cavities 
Cavity surface area 
Mean lesional score 
97 
6 
0 
2 
l/2 (50%) 
89 
87/89 (98%) 
3189 (3%) 
2/89 (2%) 
l/14 (7%) 
63.6 f 9.9 (7.1 kg)? 
13.5 f 10.1 
19/72 (26%) 
28.6 h 44.0f 
1.2 f 0.5 
109 
8 
1* 
9 
319 (33%) 
93 
91/93 (98%) 
2/93 (2%) 
2193 (2%) 
l/9 (11%) 
60.5 f 9.0 (4.4 kg)? 
P~0~0001~~ 22.4 f 18.6 
22/77 (31%) 
28.4 zt38*2§ 
1.3 f 0.6 
DR, drug-resistance; ESR, erythrocyte sedimentation rate; *Death due to tuberculosis in 
drug-resistant patient; TIncrease in body weight; iInitial mean size 98.4 f 100.7 cm2; 
reduction of 71%; @Initial mean size of 65.6 f 48.7 cm2; reduction of 57%; IlLStudent’s t-test. 
courses of re-treatment, successful in at least two 
cases, and 1 patient died during re-treatment. 
Among 12 patients lost to follow-up, one was 
smear positive for AFB at the time. Thus, the 
first course of treatment with chemotherapy plus 
an injection of M. vaccae was successful in 78 of 
85 (92%) patients. In comparison, in the placebo 
group, 13 patients required re-treatment, suc- 
cessful in three cases, but two died during 
re-treatment. Two other patients died of tuber- 
culosis, and among the 19 lost to follow-up, 
three were smear positive when lost. The first 
course of chemotherapy alone was successful in 
77 of 90 (86%) patients. 
RESULTS FOR DRUG-RESISTANT CASES 
Of the 14 patients infected with bacilli showing 
some drug resistance who received immuno- 
therapy, all appeared cured at the end of treat- 
ment but one subsequently relapsed. Among the 
11 patients infected with drug-resistant bacilli 
receiving chemotherapy alone, nine (82%) 
patients appeared to be cured at the end of 
treatment and one patient relapsed subsequently. 
One patient with multi-drug-resistant disease 
died during re-treatment and another patient 
remains with continuing disease. 
REGAIN OF BODY WEIGHT 
As well as the overall figures for weight regain 
shown in Tables 2-4, a breakdown of the data 
disclosed additional information. Complete sets 
of four weight measurements were obtained 
from 79% of M. vaccae recipients and 84% of 
placebo recipients. Four consecutive weight 
increases were seen in 34 of 77 (44%) of the 
immunotherapy group, and in 15 of 92 (16%) of 
the placebo group (P<O*OOOl, Fisher’s exact 
test), but in these two sets, the total weight 
increase was the same (10.6 f 3.8 kg and 
10.4 f 4.2 kg, respectively). Those making 
unsteady, but overall, weight increases were 36 
of 77 (74%) immunotherapy recipients and 64 of 
92 (70%) placebo recipients (P<O*Ol), with mean 
increases of 5.8 f 3.3 kg and 4.5 f 3.0 kg, 
respectively (PcO.05, Student’s t-test). 
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In the immunotherapy group, two of 77 
patients showed no overall change in weight, and 
five of 77 patients showed an overall weight loss 
of 2.4 f 0.9 kg. In the placebo group, six of 92 
patients showed no weight gain and seven of 92 
patients showed a weight loss of 4-O f 3.7 kg. 
Patients with incomplete data sets appeared to 
follow the same trends. 
RADIOLOGICAL PROGRESSION 
As well as the data in the footnotes to Tables 3 
and 4 showing better resolution of cavities in the 
M. vaccae recipient group, the data from patients 
for whom a complete set of three chest X-rays are 
available has been analysed. Of the 82 of 97 
(85%) patients with complete sets in the immuno- 
therapy group, 68 of 82 (83%) patients had visible 
cavities at the start of treatment. Of these, 59 of 
68 (87%) patients show steady resolution of cavi- 
ties with no cavitation being detectable in 49 of 68 
(72%) patients on the 1 yr X-ray. These figures 
are similar for the placebo recipient patients for 
whom 93 of 109 (85%) patients have complete 
sets; 75 of 93 (81%) patients with cavities visible 
at the start of treatment. Of these, 60 of 75 (80%) 
patients showed steady resolution, with no cavi- 
tation being detectable at 1 yr in 52 of 75 (69%) 
patients. Whereas amongst immunotherapy re- 
cipients, one of 68 patients showed no change in 
cavitation, and one of 68 patients showed slight 
deterioration over the year, in the placebo group, 
one of 75 patients showed no change and four of 
75 patients deteriorated. 
Discussion 
The groups were well matched as shown in Table 
1, although chest X-rays showed the M. vaccae 
recipients to have marginally worse disease with 
more cavitation, and there were a few more 
patients infected with bacilli showing some drug 
resistance in this group. The level of newly- 
diagnosed patients infected with multi-drug- 
resistant bacilli (resistant to isoniazid and 
rifampicin, at least) was seven of 175 patients, a 
worrying 4.0% compared with the national aver- 
age of 2*4%, and much higher than the 0.6% in 
England and Wales (8). 
As expected, where good-quality chemo- 
therapy for tuberculosis is available, the influ- 
ence of immunotherapy with M vuccae is less 
obvious than was found in Nigeria (4). Despite 
this, the benefits are not entirely hidden. 
Although, in most cases, differences at the end of 
chemotherapy were not statistically significant, 
every measure of outcome was improved by the 
immunotherapy, despite their marginally worse 
condition at the start of the study. There was a 
better bacteriological outcome with fewer requir- 
ing a course of re-treatment (P=O*O5). Recovery 
of body weight (4.4 kg c.f. 3.3 kg; P<O*O5), 
reduction in ESR (P=O*OO2) and resolution of 
cavities (P=O*OOl) were also better in the im- 
munotherapy recipients. In fact, the results 
obtained after immunotherapy were not unlike 
those achieved in Nigeria, despite the marked 
difference in chemotherapy. 
As in the studies of fully-treated patients car- 
ried out in The Gambia and Vietnam, reported in 
reviews (5,6), deaths from tuberculosis were fewer 
among those receiving A4. vaccue. If numbers of 
deaths are pooled for these earlier studies and the 
present study, seven of 306 (2.3%) patients died 
from tuberculosis amongst A4. vuccue recipients, 
compared with 21 of 323 (6.5%) patients amongst 
controls (PCO.01). Although numbers of patients 
infected with drug-resistant bacilli were too few 
to show statistically significant differences be- 
tween the two treatment groups (see Tables 24), 
the trend was in favour of those receiving 
immunotherapy (9). 
No obvious differences are shown between the 
groups in numbers of cavities or calculated sur- 
face area of walls of cavities seen on X-ray at the 
end of treatment or 6 months later, but more 
detailed study shows better progression towards 
resolution am’ongst immunotherapy recipients 
(10). In this group, 81% (79 patients) started 
with cavities compared to 77% (84 patients) in 
the control group. Leaving deaths and the small 
amount of missing data aside, these fell to 65% 
at the end of chemotherapy and to 26% and 
31%, respectively, 6 months later. Similarly, the 
areas of cavity wall still present in the study 
groups at the end of treatment or 6 months later 
did not differ, but represent reductions in cavity 
surface of 65 and 71% after immunotherapy, and 
44 and 58% without it (P<O*OOl). This is despite 
the fact that the immunotherapy group included 
the five patients with the greatest degree of initial 
cavitation. 
Patients were not tested for HIV seropositiv- 
ity, since at the time they were recruited, this was 
uncommon in Romanian adults. A small sample 
survey carried out shortly before the present 
study failed to detect any cases of HIV amongst 
tuberculosis patients. 
When the data are examined on patients 
achieving a successful outcome, those given the 
injection of M. vaccae are found to be improved 
in every parameter. Thus, differences between the 
two groups seen in Tables 2-4 do not just reflect 
differences in numbers cured bacteriologically. 
The influence of the injection goes beyond elimi- 
nation of bacilli, suggesting regulatory effects on 
release of cytokines, or to increased sensitivity to 
their effects, as shown in an experimental mouse 
model (11). Cure with chemotherapy plus im- 
munotherapy appears to be faster and more 
complete than with chemotherapy alone, drug 
resistance may have less significance, and the 
time for reducing the length of chemotherapeutic 
regimens may have been brought a little nearer. 
These observations support the concept that the 
mode of action of immunotherapy with M. 
vaccae may be on the pathway of T-helper cell 
maturation, production of type 1 cytokines, and 
the regulation of immunopathology. Why some 
patients fail to respond to treatment remains 
unclear, and may reflect differences in their 
immune response genes. 
Although not strictly blinded, the investi- 
gations providing the results were all performed 
by staff who did not know which patient had 
received which intervention. It must also be noted 
that all the patients received a chemotherapeutic 
regimen known to be highly successful, produc- 
ing in the present case 96 of 105 (91%) apparent 
cures at the end of treatment. Despite such little 
room being left available for improvement associ- 
ated with immunotherapy, at the end of chemo- 
therapy, the cure rate for h4. vaccae recipients 
was 89 of 9 1 (98%) patients, and measurements of 
every other parameter support this. 
The optimal time during chemotherapy for 
the administration of M. vaccae has yet to be 
determined with certainty. It is very likely 
that its administration earlier in the course of 
chemotherapy, even on the first day, would 
further improve the outcome of treatment. 
Studies investigating this possibility are in 
progress. 
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